6OM Stock Chart & Stats
€2.58
€0.02(0.78%)
At close: 4:00 PM EDT
€2.58
€0.02(0.78%)
Day’s Range― - ―
52-Week Range€0.78 - €4.84
Previous CloseN/A
Volume0.00
Average Volume (3M)76.00
Market Cap
€59.59M
Enterprise Value€2.07K
Total Cash (Recent Filing)€7.65M
Total Debt (Recent Filing)€1.78B
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Nov 04, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.91
Shares Outstanding76,904,700
10 Day Avg. Volume0
30 Day Avg. Volume76
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.47
Price to Sales (P/S)0.08
P/FCF Ratio-0.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.26Price Target Upside-51.06% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)0.07
Revenue Forecast (FY)€2.17B
Bulls Say, Bears Say
Bulls Say
Structural Cost ReductionRemoving more than $125 million of annualized costs can permanently lower the company’s cost base and improve operating leverage. If execution continues, these savings should support EBITDA and cash flow over the next several quarters, helping offset weaker categories and revenue pressure.
Debt Maturity ExtensionThe debt reduction and extended maturity schedule improve financial flexibility by reducing near-term refinancing pressure. No maturities until 2029 gives management more time to execute its turnaround, restore cash generation, and direct resources toward operations rather than imminent repayment needs.
Growth In Core CategoriesGrowth across sleep, diabetes, ostomy, and urology indicates that portions of the home-based care portfolio retain demand and commercial momentum. These categories provide a durable foundation for recovery, particularly as operational initiatives and new agreements expand capacity and patient volume.
Bears Say
Negative Equity And LossesNegative equity and a deeply negative net margin signal a stressed capital structure and limited financial cushion. Persistent losses can constrain investment, increase reliance on financing actions, and make the business less able to absorb further operating setbacks while management pursues recovery.
Collections And Receivables PressureLower reimbursement collection rates and worsening accounts receivable directly weaken liquidity and delay conversion of reported revenue into cash. Continued audit resolution and inefficient collection processes could remain a material drag on profitability and cash generation until remediation is sustained.
Ongoing Cash And Category WeaknessNegative operating and free cash flow leave the company dependent on operational improvement or external liquidity while respiratory and wound weakness weighs on revenue and margins. This combination increases execution risk because recovery in stronger categories must offset underperformance elsewhere.
Accendra Health News
6OM FAQ
What was Accendra Health’s price range in the past 12 months?
Accendra Health lowest stock price was €0.78 and its highest was €4.84 in the past 12 months.
What is Accendra Health’s market cap?
Accendra Health’s market cap is €59.59M.
When is Accendra Health’s upcoming earnings report date?
Accendra Health’s upcoming earnings report date is Nov 04, 2026 which is in 44 days.
How were Accendra Health’s earnings last quarter?
Accendra Health released its earnings results on Aug 10, 2026. The company reported -€0.165 earnings per share for the quarter, missing the consensus estimate of -€0.073 by -€0.092.
Is Accendra Health overvalued?
According to Wall Street analysts Accendra Health’s price is currently Overvalued.
Does Accendra Health pay dividends?
Accendra Health does not currently pay dividends.
What is Accendra Health’s EPS estimate?
Accendra Health’s EPS estimate is <0.01.
How many shares outstanding does Accendra Health have?
Accendra Health has 76,904,700 shares outstanding.
What happened to Accendra Health’s price movement after its last earnings report?
Accendra Health reported an EPS of -€0.165 in its last earnings report, missing expectations of -€0.073. Following the earnings report the stock price went down -46.522%.
Which hedge fund is a major shareholder of Accendra Health?
Currently, no hedge funds are holding shares in DE:6OM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Accendra Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€1.26 (-51.06% Downside)
€1.26 (-51.06% Downside)
Blogger Sentiment
Neutral
DE:6OM Sentiment 50%
Sector Average 63%
Sector Average 63%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-49.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Accendra Health
Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a wide array of goods and support services to both healthcare providers and manufacturers. Its extensive catalog includes medical and surgical supplies, featuring both established brands and its own proprietary merchandise. This segment also delivers crucial services to healthcare providers, such as supplier relationship management, advanced analytics, inventory optimization, and clinical supply oversight. Furthermore, it provides outsourced logistics and marketing assistance programs to its vendor partners. The Patient Direct segment is dedicated to delivering products and services for at-home patient care. Its offerings encompass critical therapeutic fields such as diabetes management, home-based respiratory support, and obstructive sleep apnea therapy. This division also supplies various other types of home medical equipment, as well as specialized patient care products for conditions like ostomy, wound management, urological needs, and incontinence. Accendra Health serves a diverse client base directly, including large multi-facility healthcare systems, independent hospitals, surgical facilities, and physicians' practices. Additionally, it reaches customers indirectly through third-party distribution channels. The enterprise was formerly known as Owens & Minor, Inc., adopting the name Accendra Health, Inc. in December 2025. Founded in 1882, its headquarters are located in Glen Allen, Virginia.
6OM Company Deck
6OM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted meaningful strategic and financial progress — notably >$125M of annualized cost reductions, a successful balance sheet optimization (debt down ~ $400M and extended maturities), improving growth in sleep and diabetes, and commercial wins and operational initiatives positioned to drive late‑2026/2027 upside. However, near‑term performance was impaired by several material operational headwinds: unusually large payor audit activity that depressed collections (≈$10M in Q2, $20M H1), worsening AR and cash pressure, category weakness in respiratory and wound, and later-than-expected timing of cost benefits. Management has clear remediation plans (cost actions, collections fixes, logistics partnerships, asset sales, ATM program) and expects a stronger Q4 and improved 2027, but the near-term mix of execution and cash challenges tempers the positive long‑term narrative.View all DE:6OM earnings summaries6OM Stock 12 Month Forecast
Average Price Target
€1.26
▼(-51.06% Downside)
Technical Analysis
Cencora
―
Cardinal Health
―
Henry Schein
―
McKesson
―
Guardian Pharmacy Services, Inc. Class A
―